Innate Pharma (IPHA) — Cash Flow Quality Index
Innate Pharma (IPHA) has a Cash Flow Quality Index of -6.67x as of June 2023. Operating cash flow of $-11.46 Million is below net income of $1.72 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore IPHA cash generation efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Innate Pharma Cash Flow Quality Index (2016–2018)
Historical Cash Flow Quality Index for Innate Pharma across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check IPHA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Innate Pharma (2016–2018)
Year-by-year earnings quality comparison for Innate Pharma. For live market cap and the full company financial profile, see IPHA company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2018 | -10.67x | $-32.53 Million | $3.05 Million | ▼ -266.0% |
| 2016 | -2.92x | $-36.85 Million | $12.64 Million | — |